Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BMRN Biomarin Pharmaceutical
112.840-3.870-3.32%
Close
02/02 16:00 ET
High
116.700
Open
116.640
Turnover
199.69M
Low
111.840
Pre Close
116.710
Volume
1.76M
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)
BioMarin Pharmaceutical Is Maintained at Outperform by SVB Leerink
BioMarin Pharmaceutical Price Target Raised to $130.00/Share From $122.00 by SVB Leerink
BioMarin Pharmaceutical Price Target Raised to $130.00/Share From $122.00 by SVB Leerink
SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $130
SVB Leerink analyst Joseph Schwartz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $122 to $130.
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by BMO Capital Markets
BMO Capital Markets assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research note published on Monday morning, The Fly reports. The brokerage issued a market per
BMO Capital Markets Begins Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN)
BMO Capital Markets began coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a market perf
International Biotechnology Trust PLC Raises Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
International Biotechnology Trust PLC raised its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 788.6% during the third quarter, according to the company in its most r
BioMarin Pharmaceutical (NASDAQ:BMRN) Receives New Coverage From Analysts at BMO Capital Markets
BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a market
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
BMO Capital Markets initiated coverage on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) with a Market Perform rating and a price target of $107.Related: BioMarin's Growth Prospects Soar with Potential Vox
BioMarin Pharmaceuticals Started at Market Perform With $107 Stock Price Target at BMO Capital
BioMarin Pharmaceuticals Started at Market Perform With $107 Stock Price Target at BMO Capital
Company Overview
More
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
CEO： Mr. Jean-Jacques Bienaime
Market： NASDAQ
Listing Date： 07/23/1999
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet